文献速递艾滋病与性传播感染

病毒学抑制的HIV-1成人大腿注射卡博特韦+利匹韦林:3b期ATLAS-2M研究子研究

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

ATLAS-2M子研究纳入118例有≥3年臀部注射经验的病毒学抑制HIV-1成人,评估大腿注射卡博特韦+利匹韦林。每2月给药组首次大腿注射部分药代参数高于臀部注射,每1月给药组无显著差异;大腿注射后无参与者HIV-1 RNA≥50拷贝/mL,4%-7%注射部位反应为3级,5例因注射部位反应或注射不耐受退出。

要点

  • 每2月给药组首次大腿注射卡博特韦的AUC与Cmax及利匹韦林首次Cmax和末次大腿注射全部参数均显著高于臀部注射。
  • 每1月给药组大腿与臀部注射药代参数无显著差异。
  • 大腿注射后无参与者HIV-1 RNA≥50拷贝/mL,4%-7%注射部位反应为3级,5例因注射部位反应或不耐受退出。

核心结论

  • 数据表明卡博特韦+利匹韦林长效肌注大腿给药有潜力用于每1月慢性/连续给药及轮换/短期每1月或每2月给药(连续给药≤4个月)的HIV-1治疗。

研究设计与样本

  • ATLAS-2M研究子研究,纳入118例有≥3年臀部注射经验的病毒学抑制HIV-1成人,分筛选、大腿注射(第1天至第16周)和恢复臀部注射(第16周至第24周)阶段,注射方案与主研究不变。

主要发现

  • 每2月给药组首次大腿注射卡博特韦的AUC和Cmax及首次大腿注射利匹韦林Cmax和末次大腿注射利匹韦林全部参数在配对比较中均统计学高于臀部注射。
  • 每1月给药组大腿注射与臀部注射相比无显著差异。
  • 大腿注射后无参与者HIV-1 RNA≥50拷贝/mL。
  • 总体4%-7%的注射部位反应为3级,5例参与者因注射部位反应或注射不耐受退出。
  • 总体30%参与者偏好大腿注射而非臀部注射。

临床怎么用

  • 作者认为数据表明卡博特韦+利匹韦林长效肌注大腿给药有潜力用于每1月慢性/连续给药及轮换/短期每1月或每2月给药(连续给药≤4个月)的HIV-1治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabotegravir + rilpivirine (CAB + RPV) administered via intramuscular gluteal injections is the first complete long-acting regimen for maintaining human immunodeficiency virus type 1 (HIV-1) virologic suppression. We present substudy results on short-term repeat intramuscular CAB + RPV long-acting thigh injections in participants with ≥3 years of experience with gluteal administration during the ATLAS-2M study. METHODS: Substudy phases included screening, thigh injection (day 1-week 16), and return to gluteal injection (week 16-week 24). The injection schedule was unchanged from the main study. Outcomes included pharmacokinetics, safety, tolerability, efficacy, and patient-reported outcomes. Pharmacokinetic parameters were determined using noncompartmental analysis and mixed-effects modeling. Population pharmacokinetic simulations were performed. RESULTS: There were 118 participants. In the arm that received injections every 2 months (Q2M), first CAB thigh injection including area under the concentration-time curve and maximum observed concentration (Cmax) and first RPV thigh injection Cmax and all last RPV thigh injection parameters were statistically higher vs gluteal injections (paired comparison). No significant differences occurred with once-monthly (QM) dosing. No participants had HIV-1 RNA ≥50 copies/mL after thigh injections. Overall, 4%-7% of injection site reactions (ISRs) were grade 3. Five participants withdrew due to an ISR or injection intolerability. Overall, 30% preferred thigh vs gluteal injections. Simulations demonstrated the potential for chronic/continuous QM or ≤2 consecutive Q2M thigh injections. CONCLUSIONS: These data demonstrate the potential use of chronic/continuous QM and rotational/short-term QM or Q2M (≤4 months of continuous dosing), CAB + RPV long-acting intramuscular thigh administration for HIV-1 treatment.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ford SL, Felizarta F, Han K, et al. Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study. Clin Infect Dis. 2025. PMID: 39878031. doi:10.1093/cid/ciae620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。